Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Whole-Body Irradiation 5Mycophenolic Acid 4Tacrolimus 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Cyclosporine 3Busulfan 3fludarabine 2apixaban 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2CT-P10 2Biopsy 2Azacitidine 2venetoclax 1thymoglobulin 1merphos 1ivosidenib 1ibrutinib 1edoxaban 1Vorinostat 1Vancomycin 1Thiotepa 1Teicoplanin 1TAK-243 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacogenomic Testing × Classical hematology × 30 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡